We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) closed the most recent trading day at $9.15, moving -1.05% from the previous trading session. This change lagged the S&P 500's daily gain of 0.72%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq added 0.71%.
Prior to today's trading, shares of the company had gained 26.89% over the past month. This has outpaced the Medical sector's loss of 0.66% and the S&P 500's gain of 0.28% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. The company is expected to report EPS of -$0.05, down 25% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $61.42 million, up 382.06% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.17 per share and revenue of $224.47 million. These totals would mark changes of -241.67% and +417.53%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for ACB. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 5.05% lower. ACB is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ACB in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
Aurora Cannabis Inc. (ACB - Free Report) closed the most recent trading day at $9.15, moving -1.05% from the previous trading session. This change lagged the S&P 500's daily gain of 0.72%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq added 0.71%.
Prior to today's trading, shares of the company had gained 26.89% over the past month. This has outpaced the Medical sector's loss of 0.66% and the S&P 500's gain of 0.28% in that time.
Wall Street will be looking for positivity from ACB as it approaches its next earnings report date. The company is expected to report EPS of -$0.05, down 25% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $61.42 million, up 382.06% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.17 per share and revenue of $224.47 million. These totals would mark changes of -241.67% and +417.53%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for ACB. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 5.05% lower. ACB is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ACB in the coming trading sessions, be sure to utilize Zacks.com.